Athersys, inc / new (ATHX)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Operating activities
Net loss

-44,582

-24,283

-32,241

-15,337

-16,422

-22,082

-30,743

-14,735

-13,746

-11,377

-15,366

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

698

855

684

382

267

360

346

320

278

284

233

Gain from forgiveness of note payable

-

-

-

190

-

-

-

-

-

-

-

Gain on sale of equipment

-

-

-

-

-

-

-

-

-

-

21

Realized gain on investments and available-for-sale securities

-

-

-

-

-

-

-

183

55

-

-

Stock-based compensation

4,851

3,849

3,044

2,900

2,929

2,605

1,523

481

552

1,466

2,808

Discount on revenue from issuance of warrant

0

1,080

0

0

-

-

-

-

-

-

-

Other

0

0

22

-2

-23

-

-

-

-

-

-

Stock–based patent license and settlement expense

0

315

3,150

0

-

-

-

1,005

683

-

-

Deferred tax benefit

-

-

-

-

-

-200

-

-

-

-

-

Gain from insurance proceeds, net

0

617

0

700

-

-

-

-

-

-

-

Change in fair value of warrant liabilities

0

0

-728

557

-772

-

-

-

-

-

-

Change in fair value of warrant liabilities

-

-

-

-

-

-6,591

6,324

-2,404

-812

-

-

Other

-

-

-

-

-

-

-

14

-

-

-

Amortization of premium on available-for-sale securities and other

-

-

-

-

-

-

-

-

-58

-225

-305

Changes in operating assets and liabilities:
Accounts receivable

-

-

-

237

-333

174

30

-199

-1,745

1,853

92

Receivable from Angiotech

-

-

-

-

-

-

-

-

-

-

-5

Prepaid expenses, deposits and other

-857

1,346

206

462

-4

33

94

-580

511

63

-449

Accounts payable and accrued expenses

-

-

-

2,413

-296

335

-196

198

983

562

479

Advances and deposits from Healios

-

-

-

0

-

-

-

-

-

-

-

Deferred revenue - Healios

-

-

-

-245

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

170

-11

86

-3,140

-3,664

165

6,581

Net cash used in operating activities

-

-

-

-

-13,764

-25,791

-22,784

-17,665

-

-

-

Net cash used in operating activities

-35,326

-13,350

-24,018

-10,931

-

-

-

-

-14,489

-10,591

-4,619

Investing activities
Purchase of available-for-sale securities

-

-

-

16,343

-

-

-

-

-

-

-

Sales of available-for-sale securities

-

-

-

16,305

-

-

-

-

-

-

-

Purchase of available-for-sale securities

-

-

-

-

-

-

-

-

12,508

8,834

11,692

Proceeds from insurance, net

0

617

0

682

-

-

-

-

-

-

-

Proceeds from maturities of available-for-sale securities

-

-

-

-

-

-

-

4,237

21,672

10,753

15,300

Investment in privately-held company

-

-

-

-

-

-

-

-

-

-

14

Proceeds from sale of equipment

-

-

-

-

-

-

-

-

-

-

21

Purchases of equipment

579

1,532

285

1,711

132

297

385

347

590

390

381

Net cash used in investing activities

-

-

-

-

-132

-297

-385

3,890

-

-

-

Net cash used in investing activities

-579

-915

-285

-1,067

-

-

-

-

8,574

1,529

3,234

Financing activities
Proceeds from Issuance of Common Stock

-

-

-

4,028

10,310

-

-

30,357

12,595

-

-

Proceeds from issuance of common stock and warrants, net

-

-

-

-

-

19,621

29,454

-

-

-

-

Proceeds from exercise of warrants

0

0

1,862

163

976

938

402

-

0

-

-

Shares retained for withholding tax payments on stock-based awards

424

402

283

467

490

-

-

-

-

-

-

Purchase of treasury stock

-

-

-

-

-

292

272

-

0

-

-

Proceeds from note payable

-

-

-

-

-

-

-

166

0

-

-

Net cash provided by financing activities

-

-

-

-

10,796

20,267

29,584

30,523

-

-

-

Net cash provided by financing activities

19,887

36,008

38,866

3,724

-

-

-

-

12,595

-

-

Decrease in cash and cash equivalents

-16,018

21,743

14,563

-

-

-

-

-

-

-

-

Increase (decrease) in cash and cash equivalents

-

-

-

-8,274

-3,100

-5,821

6,415

16,748

6,680

-9,062

-1,385

Consolidated entity excluding, related party
Accounts receivable

-245

-324

-12

-

-

-

-

-

-

-

-

Healios
Accounts receivable

-3,783

4,545

153

-

-

-

-

-

-

-

-

Accounts payable to Healios

1,068

0

0

-

-

-

-

-

-

-

-

Advances and deposits from Healios

199

4,889

134

-

-

-

-

-

-

-

-

Deferred revenue - Healios

-609

2,110

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net

0

20,995

0

-

-

-

-

-

-

-

-

Healios License Agreement
Accounts receivable

-

-

-

0

-

-

-

-

-

-

-

Deferred revenue

-

-

-

0

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net

-

-

-

0

-

-

-

-

-

-

-

Consolidated entity, excluding related party
Accounts payable and accrued expenses

-1,836

4,269

1,537

-

-

-

-

-

-

-

-

Deferred revenue

0

-250

771

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net

20,311

15,415

37,287

-

-

-

-

-

-

-

-